STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Exclusion Criteria

• •Female patients pregnant or lactating
• •Female patients of childbearing potential not using or not willing to use effective contraception
• •Presence of a second malignancy other than nonmelanoma skin cancer
• •Presence of a clinically significant and uncontrolled infection
• •Presence of clinically significant arrythmias
• •Presence of serious concurrent illness or other conditions that do not permit adequate follow-up and compliance with protocol
• •History of severe hypersensitivity reactions to taxanes
• •Use of any investigational agents within 4 weeks prior to the first dose of study drug